RxDoctor Payments Data

Thomas Johnson, MD

Ophthalmology · Miami, FLNPI 1477578680

Payments from drug & device makers

$35,060in general payments, 2019–2025

Across 59 payments — averaging $594.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$24K
  • Argenx US, Inc.$9K
  • Tarsus Pharmaceuticals, Inc.$1K
  • Amgen$423
  • Genentech USA, Inc.$205
  • AbbVie$175
  • plus $379 from 6 others

What the payments were for

  • Consulting fees$1,00045%
  • Food & beverage$1,24255%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca3$24,320
Argenx US, Inc.37$8,525
Tarsus Pharmaceuticals, Inc.2$1,034
Amgen5$423
Genentech USA, Inc.2$205
AbbVie(2 entities)2$175
Alcon1$148
Poriferous LLC1$116
Mallinckrodt Hospital Products Inc.3$62
Biotissue Holdings Inc.1$24
Katalyst Surgical, LLC1$15
Mallinckrodt Enterprises LLC1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$35,060 in reported general payments places this provider in the 85th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$66,647
Medicare patients
174
Services billed
430

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine11$6,252
Cyclosporine14$2,233
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha144$1,707
ErythromycinErythromycin Base86$1,080
Prednisolone Acetate13$358
Bacitracin-PolymyxinBacitracin/Polymyxin B Sulfate14$160

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$175$6,25211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →